Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.
One in 4 Americans >40 years of age takes a statin to reduce the risk of myocardial infarction, ischemic stroke, and other complications of atherosclerotic disease. The most effective statins produce a mean reduction in low-density lipoprotein cholesterol of 55% to 60% at the maximum dosage, and 6 of the 7 marketed statins are available in generic form, which makes them affordable for most patients. Primarily using data from randomized controlled trials, supplemented with observational data where necessary, this scientific statement provides a comprehensive review of statin safety and tolerability. The review covers the general patient population, as well as demographic subgroups, including the elderly, children, pregnant women, East Asians, and patients with specific conditions such as chronic disease of the kidney and liver, human immunodeficiency viral infection, and organ transplants. The risk of statin-induced serious muscle injury, including rhabdomyolysis, is
Arteriosclerosis, thrombosis, and vascular biology
American Heart Association; Cerebral Hemorrhage; Diabetes Mellitus; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Liver; Muscular Diseases; Randomized Controlled Trials as Topic; Rhabdomyolysis; United States
AHA Scientific Statements; cognitive function; diabetes; drug interactions; erectile dysfunction; hemorrhagic stroke; muscle; nocebo; statin intolerance; statin safety
Newman CB, Preiss D, Tobert JA, et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association [published correction appears in Arterioscler Thromb Vasc Biol. 2019 May;39(5):e158]. Arterioscler Thromb Vasc Biol. 2019;39(2):e38-e81. doi:10.1161/ATV.0000000000000073